PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 69 filers reported holding PROTAGONIST THERAPEUTICS INC in Q2 2018. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $942,000 | +21.5% | 39,771 | +75.6% | 0.00% | – |
| Q4 2021 | $775,000 | +114.1% | 22,651 | +10.8% | 0.00% | – |
| Q3 2021 | $362,000 | -88.7% | 20,434 | -71.4% | 0.00% | -100.0% |
| Q2 2021 | $3,204,000 | +207.8% | 71,400 | +77.6% | 0.00% | +100.0% |
| Q1 2021 | $1,041,000 | +6.4% | 40,199 | -17.1% | 0.00% | 0.0% |
| Q4 2020 | $978,000 | +670.1% | 48,502 | +170.5% | 0.00% | – |
| Q1 2020 | $127,000 | -0.8% | 17,931 | -1.5% | 0.00% | – |
| Q4 2019 | $128,000 | -39.3% | 18,199 | +3.7% | 0.00% | – |
| Q3 2019 | $211,000 | +1.0% | 17,555 | +1.9% | 0.00% | – |
| Q2 2019 | $209,000 | -2.8% | 17,233 | +0.6% | 0.00% | – |
| Q1 2019 | $215,000 | +70.6% | 17,127 | -8.3% | 0.00% | – |
| Q4 2018 | $126,000 | -36.7% | 18,680 | -3.6% | 0.00% | – |
| Q3 2018 | $199,000 | +27.6% | 19,382 | -16.3% | 0.00% | – |
| Q2 2018 | $156,000 | – | 23,157 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $56,331,209 | 18.32% |
| Kynam Capital Management, LP | 1,375,000 | $31,625,000 | 4.08% |
| BVF INC/IL | 3,775,900 | $86,845,700 | 3.18% |
| Cormorant Asset Management, LP | 1,700,000 | $39,100 | 2.58% |
| RTW INVESTMENTS, LP | 4,600,799 | $105,818,377 | 2.20% |
| Ghost Tree Capital, LLC | 225,000 | $5,175,000 | 1.53% |
| 683 Capital Management, LLC | 791,000 | $18,193,000 | 1.36% |
| Ikarian Capital, LLC | 211,400 | $4,862,200 | 1.10% |
| Ikarian Capital, LLC | 211,400 | $4,862,200 | 1.10% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 105,486 | $2,426,178 | 1.00% |